{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:33:48Z","timestamp":1793230428575,"version":"4.5.0"},"reference-count":25,"publisher":"Association of Basic Medical Sciences of FBIH","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Cholangiocarcinoma (CCA) exhibits diverse responses to chemotherapy, underscoring the need for drug sensitivity biomarkers. This proof-of-concept study utilized Fourier transform infrared (FTIR) spectral features to identify ex vivo\u00a0gemcitabine sensitivity and resistance, as determined by the histoculture drug response assay (HDRA). We analyzed ten formalin-fixed paraffin-embedded tumor samples and 21 serum samples (including seven matched pairs) using synchrotron radiation-based FTIR microspectroscopy and attenuated total reflectance FTIR spectroscopy, respectively. Tissue and serum spectra were evaluated using partial least squares discriminant analysis and principal component analysis, respectively, alongside patient-level spectral ratio comparisons. Both sample types primarily displayed differences in the protein-associated amide I and II regions, with additional variations in carbohydrate- and nucleic acid-associated regions. Tissue spectra demonstrated partial group separation, while serum spectra showed exploratory separation with some overlap. Three serum intensity ratios (1633\/1649\u00a0cm\u207b\u00b9, 1539\/1649\u00a0cm\u207b\u00b9, and 1539\/1633\u00a0cm\u207b\u00b9) remained significantly different after Benjamini\u2013Hochberg correction (adjusted p\u00a0= 0.041 for each), whereas no significant differences were observed in tissue ratios. Serum-based FTIR spectroscopy shows preliminary promise as a less invasive method for identifying spectral features linked to HDRA-defined gemcitabine sensitivity in CCA. However, these findings do not establish clinical predictive utility and require validation in larger cohorts with comprehensive treatment-response data.<\/jats:p>","DOI":"10.17305\/bb.2026.14765","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:46:11Z","timestamp":1791362771000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum FTIR spectral features associated with HDRA-defined gemcitabine sensitivity in cholangiocarcinoma"],"prefix":"10.17305","author":[{"given":"Kanokporn","family":"Matra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patutong","family":"Chatchawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molin","family":"Wongwattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patipat","family":"Rachawangmuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutthiwan","family":"Janthamala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaphong","family":"Rattanathip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-1945","authenticated-orcid":false,"given":"Sirinart","family":"Chio-Srichan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchai","family":"Hongsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinee","family":"Thanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supakan","family":"Amontailak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7581-7682","authenticated-orcid":false,"given":"Juthamas","family":"Jaimanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-8700","authenticated-orcid":false,"given":"Piyapong","family":"Simtong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Techasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"91728","doi-asserted-by":"crossref","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z","DOI":"10.1038\/s41575-020-0310-z"},{"key":"91729","doi-asserted-by":"crossref","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2","DOI":"10.1038\/s41572-021-00300-2"},{"key":"91730","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"91731","doi-asserted-by":"crossref","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721","DOI":"10.1056\/NEJMoa0908721"},{"key":"91732","doi-asserted-by":"crossref","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8). https:\/\/doi.org\/10.1056\/EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015"},{"key":"91733","doi-asserted-by":"crossref","unstructured":"Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:108\u201322. https:\/\/doi.org\/10.1111\/liv.14090","DOI":"10.1111\/liv.14090"},{"key":"91734","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105\u201319. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.021"},{"key":"91735","doi-asserted-by":"crossref","unstructured":"Baker MJ, Trevisan J, Bassan P, Bhargava R, Butler HJ, Dorling KM, et al. Using Fourier transform IR spectroscopy to analyze biological materials. Nat Protoc. 2014;9(8):1771\u201391. https:\/\/doi.org\/10.1038\/nprot.2014.110","DOI":"10.1038\/nprot.2014.110"},{"key":"91736","doi-asserted-by":"crossref","unstructured":"Su KY, Lee WL. Fourier transform infrared spectroscopy as a cancer screening and diagnostic tool: a review and prospects. Cancers (Basel). 2020;12(1):115. https:\/\/doi.org\/10.3390\/cancers12010115","DOI":"10.3390\/cancers12010115"},{"key":"91737","doi-asserted-by":"crossref","unstructured":"Talari ACS, Martinez MAG, Movasaghi Z, Rehman S, Rehman IU. Advances in Fourier transform infrared (FTIR) spectroscopy of biological tissues. Appl Spectrosc Rev. 2017;52(5):456\u2013506. https:\/\/doi.org\/10.1080\/05704928.2016.1230863","DOI":"10.1080\/05704928.2016.1230863"},{"key":"91738","doi-asserted-by":"crossref","unstructured":"Kazarian SG, Chan KLA. ATR-FTIR spectroscopic imaging: recent advances and applications to biological systems. Analyst. 2013;138(7):1940\u201351. https:\/\/doi.org\/10.1039\/c3an36865c","DOI":"10.1039\/c3an36865c"},{"key":"91739","doi-asserted-by":"crossref","unstructured":"Wongwattanakul M, Hahnvajanawong C, Seubwai W, Leelayuwat C, Limpaiboon T, Jearanaikoon P. Potential prediction of patient survival and chemotherapeutic sensitivity in cholangiocarcinoma using FTIR microspectroscopy. J Mol Struct. 2018;1166:416\u201321. https:\/\/doi.org\/10.1016\/j.molstruc.2018.04.044","DOI":"10.1016\/j.molstruc.2018.04.044"},{"key":"91740","doi-asserted-by":"crossref","unstructured":"Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, et al. Monitoring the progression of liver fluke-induced cholangiocarcinoma in a hamster model using synchrotron FTIR microspectroscopy and focal plane array infrared imaging. Anal Chem. 2020;92(23):15361\u20139. https:\/\/doi.org\/10.1021\/acs.analchem.0c02656","DOI":"10.1021\/acs.analchem.0c02656"},{"key":"91741","doi-asserted-by":"crossref","unstructured":"Suksawat M, Klanrit P, Phetcharaburanin J, Namwat N, Khuntikeo N, Titapun A, et al. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS One. 2019;14(9). https:\/\/doi.org\/10.1371\/journal.pone.0222140","DOI":"10.1371\/journal.pone.0222140"},{"key":"91742","doi-asserted-by":"crossref","unstructured":"Chio-Srichan S, Attarataya J, Phonthongchanthuek T, Tarawarakarn P, Srisamut D, Chantarakorn C, et al. Design and performance of the first infrared beamline at Siam Photon Laboratory (SPL), Thailand. Infrared Phys Technol. 2026;152:106248. https:\/\/doi.org\/10.1016\/j.infrared.2025.106248","DOI":"10.1016\/j.infrared.2025.106248"},{"key":"91743","doi-asserted-by":"crossref","unstructured":"Kluz-Bar\u0142owska M, Kluz T, Paja W, Sarzy\u0144ski J, Barna\u015b E, \u0141\u0105czy\u0144ska-Madera M, et al. Determination of platinum-resistance of women with ovarian cancer by FTIR spectroscopy combined with multivariate analyses and machine learning methods. Sci Rep. 2024;14(1):24923. https:\/\/doi.org\/10.1038\/s41598-024-76965-y","DOI":"10.1038\/s41598-024-76965-y"},{"key":"91744","doi-asserted-by":"crossref","unstructured":"Kluz-Bar\u0142owska M, Kluz T, Paja W, Pancerz K, \u0141\u0105czy\u0144ska-Madera M, Miziak P, et al. FT-Raman and FTIR spectroscopy as a tools showing marker of platinum-resistant phenomena in women suffering from ovarian cancer. Sci Rep. 2024;14(1):11025. https:\/\/doi.org\/10.1038\/s41598-024-61775-z","DOI":"10.1038\/s41598-024-61775-z"},{"key":"91745","doi-asserted-by":"crossref","unstructured":"Wongwattanakul M, Hahnvajanawong C, Tippayawat P, Chio-Srichan S, Leelayuwat C, Limpaiboon T, et al. Classification of gemcitabine resistant cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy. J Biophotonics. 2017;10(3):367\u201376. https:\/\/doi.org\/10.1002\/jbio.201500253","DOI":"10.1002\/jbio.201500253"},{"key":"91746","doi-asserted-by":"crossref","unstructured":"Bonnier F, Baker MJ, Byrne HJ. Vibrational spectroscopic analysis of body fluids: avoiding molecular contamination using centrifugal filtration. Anal Methods. 2014;6(14):5155\u201360. https:\/\/doi.org\/10.1039\/c4ay00891j","DOI":"10.1039\/c4ay00891j"},{"key":"91747","doi-asserted-by":"crossref","unstructured":"Kidoikhammouan S, Saengboonmee C, Wongkham S, Seubwai W. Molecular mechanisms of gemcitabine resistance in cholangiocarcinoma. Oncol Res. 2025;33(12):3679\u201399. https:\/\/doi.org\/10.32604\/or.2025.069027","DOI":"10.32604\/or.2025.069027"},{"key":"91748","doi-asserted-by":"crossref","unstructured":"De Meutter J, Goormaghtigh E. Amino acid side chain contribution to protein FTIR spectra: impact on secondary structure evaluation. Eur Biophys J. 2021;50(3\u20134):641\u201351. https:\/\/doi.org\/10.1007\/s00249-021-01507-7","DOI":"10.1007\/s00249-021-01507-7"},{"key":"91749","unstructured":"Chen YJ, Hsieh YW, Cheng YD, Liao CC. Study on the secondary structure of protein in amide I band from human colon cancer tissue by Fourier-transform infrared spectroscopy. Chang Gung Med J. 2001;24(9):541\u20136. PMID: 11725623"},{"key":"91750","doi-asserted-by":"crossref","unstructured":"Baran Y, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomed Pharmacother. 2013;67(3):221\u20137. https:\/\/doi.org\/10.1016\/j.biopha.2012.12.001","DOI":"10.1016\/j.biopha.2012.12.001"},{"key":"91751","doi-asserted-by":"crossref","unstructured":"Suksawat M, Phetcharaburanin J, Klanrit P, Namwat N, Khuntikeo N, Titapun A, et al. Metabolic phenotyping predicts gemcitabine and cisplatin chemosensitivity in patients with cholangiocarcinoma. Front Public Health. 2022;10:766023. https:\/\/doi.org\/10.3389\/fpubh.2022.766023","DOI":"10.3389\/fpubh.2022.766023"},{"key":"91752","doi-asserted-by":"crossref","unstructured":"Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S. Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget. 2015;6(17):14744\u201353. https:\/\/doi.org\/10.18632\/oncotarget.4539","DOI":"10.18632\/oncotarget.4539"}],"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14765\/4348","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14765\/4348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:47Z","timestamp":1793228447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/14765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":25,"URL":"https:\/\/doi.org\/10.17305\/bb.2026.14765","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}